These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 22928577)

  • 1. Short-term intensified insulin treatment in type 2 diabetes: long-term effects on β-cell function.
    Retnakaran R; Zinman B
    Diabetes Obes Metab; 2012 Oct; 14 Suppl 3():161-6. PubMed ID: 22928577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current role of short-term intensive insulin strategies in newly diagnosed type 2 diabetes.
    Xu W; Weng J
    J Diabetes; 2013 Sep; 5(3):268-74. PubMed ID: 23551748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of reversibility of β-cell dysfunction in response to short-term intensive insulin therapy in patients with early type 2 diabetes.
    Kramer CK; Choi H; Zinman B; Retnakaran R
    Am J Physiol Endocrinol Metab; 2013 Dec; 305(11):E1398-407. PubMed ID: 24129396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a combination of oral anti-diabetes drugs with basal insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes.
    Mu PW; Chen YM; Lu HY; Wen XQ; Zhang YH; Xie RY; Shu J; Wang MM; Zeng LY
    Diabetes Metab Res Rev; 2012 Mar; 28(3):236-40. PubMed ID: 21898754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of beta-cell function with oral antidiabetic medications: a pilot study with sitagliptin.
    Retnakaran R; Qi Y; Opsteen C; Vivero E; Zinman B
    Diabetes Obes Metab; 2010 Oct; 12(10):909-15. PubMed ID: 20920044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in the treatment of type 2 diabetes mellitus.
    Israili ZH
    Am J Ther; 2011; 18(2):117-52. PubMed ID: 19834322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initiating insulin in patients with type 2 diabetes.
    Aoki TJ; White RD
    J Fam Pract; 2007 Aug; 56(8 Suppl Hot Topics):S12-20. PubMed ID: 18667139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of beta-cell management in type 2 diabetes.
    Standl E
    Int J Clin Pract Suppl; 2007 Jun; (153):10-9. PubMed ID: 17594389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection of pancreatic beta-cells: is it feasible?
    Bonora E
    Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of type 2 diabetes with combined therapy: what are the pros and cons?
    Massi-Benedetti M; Orsini-Federici M
    Diabetes Care; 2008 Feb; 31 Suppl 2():S131-5. PubMed ID: 18227473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Redefining insulin therapy in type 2 diabetes mellitus.
    Rosenstock J
    Postgrad Med; 2004 Nov; 116(5 Suppl Exploring):21-9. PubMed ID: 19667676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin therapy for management of type 2 diabetes mellitus: strategies for initiation and long-term patient adherence.
    Barag SH
    J Am Osteopath Assoc; 2011 Jul; 111(7 Suppl 5):S13-9. PubMed ID: 21813731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fate of the beta-cell in the pathophysiology of type 2 diabetes.
    Campbell RK
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S10-5. PubMed ID: 19801360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy?
    van Raalte DH; Diamant M
    Diabetes Res Clin Pract; 2011 Aug; 93 Suppl 1():S37-46. PubMed ID: 21864750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
    Dailey G
    Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.
    Mu J; Woods J; Zhou YP; Roy RS; Li Z; Zycband E; Feng Y; Zhu L; Li C; Howard AD; Moller DE; Thornberry NA; Zhang BB
    Diabetes; 2006 Jun; 55(6):1695-704. PubMed ID: 16731832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The intriguing effects of time to glycemic goal in newly diagnosed type 2 diabetes after short-term intensive insulin therapy.
    Cheng L; Xu M; Lin X; Tang J; Qi Y; Wan Y; Pan X; Chen X; Ren M; Yan L
    Endocr J; 2016 Aug; 63(8):739-46. PubMed ID: 27334121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-cell function and mass in type 2 diabetes.
    Larsen MO
    Dan Med Bull; 2009 Aug; 56(3):153-64. PubMed ID: 19728971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term maintenance of glucose control in veterans with type 2 diabetes mellitus using oral agents.
    Swislocki AL; Meier JL; Najera SM; Noth RH
    Metab Syndr Relat Disord; 2011 Dec; 9(6):469-73. PubMed ID: 21864034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of intensified metabolic control on CNS function in type 2 diabetes.
    Cooray G; Nilsson E; Wahlin A; Laukka EJ; Brismar K; Brismar T
    Psychoneuroendocrinology; 2011 Jan; 36(1):77-86. PubMed ID: 20656408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.